GYRE Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 19.52%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $799,621.30

Gyre Therapeutics Insider Trading History Chart

Gyre Therapeutics Share Price & Price History

^$8.88

▲ +0.94 (11.84%)

As of 04/17/2025 05:00 PM ET

Days: 30 | 90 | 365

Gyre Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/19/2025	Songjiang Ma	President	Sell	2,000	$10.13	$20,260.00	2,827,018
3/17/2025	Songjiang Ma	President	Sell	2,000	$12.09	$24,180.00	2,829,260
3/14/2025	Songjiang Ma	President	Sell	2,000	$12.31	$24,620.00	2,831,260
3/12/2025	Songjiang Ma	President	Sell	2,000	$11.74	$23,480.00	2,835,260
3/10/2025	Songjiang Ma	President	Sell	2,000	$10.14	$20,280.00	2,839,260
3/7/2025	Songjiang Ma	President	Sell	2,000	$10.25	$20,500.00	2,841,260
2/10/2025	Songjiang Ma	President	Sell	2,000	$11.90	$23,800.00	2,877,138
2/4/2025	Songjiang Ma	President	Sell	2,000	$11.62	$23,240.00	2,885,138
1/29/2025	Songjiang Ma	President	Sell	2,000	$11.43	$22,860.00	2,893,138
1/27/2025	Songjiang Ma	President	Sell	2,000	$11.18	$22,360.00	2,897,138
1/23/2025	Songjiang Ma	President	Sell	2,000	$10.49	$20,980.00	2,901,138
1/21/2025	Songjiang Ma	President	Sell	2,000	$10.85	$21,700.00	2,905,138
1/17/2025	Songjiang Ma	President	Sell	2,000	$10.72	$21,440.00	2,907,138
1/15/2025	Songjiang Ma	President	Sell	2,000	$10.85	$21,700.00	2,911,138
1/13/2025	Songjiang Ma	President	Sell	56	$10.10	$565.60	2,915,138
1/10/2025	Songjiang Ma	President	Sell	1,057	$10.02	$10,591.14	2,915,194
1/6/2025	Songjiang Ma	President	Sell	941	$10.16	$9,560.56	2,917,526
1/2/2025	Songjiang Ma	President	Sell	2,000	$12.40	$24,800.00	2,920,467
12/30/2024	Songjiang Ma	President	Sell	2,000	$12.50	$25,000.00	2,924,467
12/26/2024	Songjiang Ma	President	Sell	2,000	$12.70	$25,400.00	2,928,467
12/23/2024	Songjiang Ma	President	Sell	2,000	$12.27	$24,540.00	2,932,467
12/19/2024	Songjiang Ma	President	Sell	2,000	$10.82	$21,640.00	2,936,467
12/17/2024	Songjiang Ma	President	Sell	2,000	$11.05	$22,100.00	2,940,467
6/28/2024	Nassim Usman	Director	Sell	3,452	$12.00	$41,424.00	1,636
5/1/2024	Nassim Usman	Director	Sell	20,000	$14.13	$282,600.00	1,636
1/3/2024	Songjiang Ma	President	Sell	833	$11.85	$9,871.05	2,918,467

See Full Table

SEC Filings (Institutional Ownership Changes) for Gyre Therapeutics (NASDAQ:GYRE)

23.99% of Gyre Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Gyre Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/7/2025	GAMMA Investing LLC	1,822	$0.14M	0.0%	+15,083.3%	0.002%
2/17/2025	Bank of America Corp DE	6,937	$84K	0.0%	+40.4%	0.007%
2/14/2025	Northern Trust Corp	103,382	$1.25M	0.0%	+9.1%	0.111%
2/13/2025	Barclays PLC	10,543	$0.13M	0.0%	+13.5%	0.011%
2/13/2025	Wells Fargo & Company MN	4,016	$49K	0.0%	+29.4%	0.004%
2/11/2025	Advantage Alpha Capital Partners LP	8,873	$0.11M	0.0%	-66.7%	0.009%
2/6/2025	Charles Schwab Investment Management Inc.	114,566	$1.39M	0.0%	+0.8%	0.123%
2/6/2025	SBI Securities Co. Ltd.	101,239	$1.23M	0.0%	N/A	0.108%
2/4/2025	Bank of New York Mellon Corp	13,896	$0.17M	0.0%	+11.1%	0.015%
11/19/2024	Barclays PLC	9,288	$0.12M	0.0%	+281.8%	0.010%
11/16/2024	Geode Capital Management LLC	303,647	$3.81M	0.0%	+16.9%	0.325%
11/15/2024	Barclays PLC	9,288	$0.12M	0.0%	+281.8%	0.010%
11/15/2024	State Street Corp	104,490	$1.31M	0.0%	+8.8%	0.112%
11/13/2024	FMR LLC	3,742	$47K	0.0%	N/A	0.004%
11/13/2024	Advantage Alpha Capital Partners LP	26,634	$0.33M	0.1%	N/A	0.029%
11/12/2024	Charles Schwab Investment Management Inc.	113,648	$1.43M	0.0%	+392.2%	0.122%
8/14/2024	Marshall Wace LLP	10,720	$0.13M	0.0%	-58.0%	0.013%
8/9/2024	Renaissance Technologies LLC	13,900	$0.17M	0.0%	N/A	0.016%
8/9/2024	WINTON GROUP Ltd	18,467	$0.22M	0.0%	N/A	0.022%
8/1/2024	Rhumbline Advisers	10,291	$0.12M	0.0%	N/A	0.012%
7/26/2024	Bank of New York Mellon Corp	18,266	$0.22M	0.0%	N/A	0.021%
5/10/2024	Vanguard Group Inc.	195,098	$3.41M	0.0%	-1.5%	0.228%

Data available starting January 2016

See Full Table

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Today's Range

Now: $8.88

$7.92

$8.97

50 Day Range

MA: $9.81

$6.41

$12.62

52 Week Range

Now: $8.88

$6.11

$19.00

Volume

103,334 shs

Average Volume

92,027 shs

Market Capitalization

$831.27 million

P/E Ratio

177.60

Dividend Yield

N/A

Beta

2.03

Who are the company insiders with the largest holdings of Gyre Therapeutics?: Gyre Therapeutics' top insider investors include:
Songjiang Ma (President)
Nassim Usman (Director)
Learn More about top insider investors at Gyre Therapeutics.
Who are the major institutional investors of Gyre Therapeutics?: Gyre Therapeutics' top institutional shareholders include:
GAMMA Investing LLC — 0.00%
Learn More about top institutional investors of Gyre Therapeutics stock.
Which major investors are buying Gyre Therapeutics stock?: In the last quarter, GYRE stock was acquired by institutional investors including:
GAMMA Investing LLC